COMPASS Pathways plc (CMPS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Care Facilities Branche. Der Hauptsitz des Unternehmens ist in London, United Kingdom. Der aktuelle CEO ist Kabir Kumar Nath.
CMPS hat IPO-Datum 2020-09-18, 166 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $572.67M.
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
